Clinical trial NCT00671307 - References

Infection — Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels

Citation(s)

•   Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ
  Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med. 2002 Jan;50(1):54-60.
•   DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH
  Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002 Dec 15;100(13):4367-71. Epub 2002 Aug 1.
•   Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO
  Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006 Mar;243(3):399-403.
•   Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP
  Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007 Mar;35(3):849-55.
•   Mounzer KC, Moncure M, Smith YR, Dinubile MJ
  Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1673-81.
•   Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH
  Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol (1985). 2004 Jan;96(1):25-31. Epub 2003 May 2.
•   Suhler E, Lin W, Yin HL, Lee WM
  Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997 Apr;25(4):594-8.

Phase 1b Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels

Details for clinical trial NCT00671307